Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments

Lorena P. Suarez-Kelly, Giacomo G. Baldi, Alessandro Gronchi

Research output: Contribution to journalReview article

Abstract

Introduction: Liposarcomas are a heterogeneous group of soft tissue tumors that arise from adipose tissue and are one of the most common soft tissue sarcomas found in adults. Liposarcomas are subclassified into four subtypes with distinct histologic and biologic features that influence their treatment and management. Areas covered: This manuscript reviews the key clinicopathologic and cytogenic characteristics of the liposarcoma histologic subtypes and summarizes the results of recent clinical trials, treatment options, and future directions in the pharmacotherapy for the management of liposarcoma. Expert opinion: Despite significant advancements in the management of this disease, the treatment of liposarcoma continues to be a challenge. Surgical resection remains the mainstay of treatment for localized disease; however, use of systemic therapies in conjunction with surgery may be considered in patients where tumor shrinkage could reduce surgical morbidity and in patients with high-risk of micrometastatic disease. Anthracycline-based chemotherapy regimens remain the standard first-line treatment for unresectable/metastatic liposarcoma. Trabectedin and eribulin are currently the two most promising and evidenced-based second-line treatment options for liposarcomas. However, multiple clinical trials dedicated to patients with liposarcoma evaluating novel targeted agents are ongoing. Every effort should be made to enroll patients with liposarcoma into histotype-specific clinical trials.

Original languageEnglish
Pages (from-to)1503-1515
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume20
Issue number12
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Liposarcoma
Drug Therapy
trabectedin
Therapeutics
eribulin
Clinical Trials
Anthracyclines
Expert Testimony
Disease Management
Sarcoma
Adipose Tissue
Neoplasms
Morbidity

Keywords

  • Cytotoxic Chemotherapy
  • liposarcoma
  • myxoid/round cell
  • pleomorphic
  • targeted therapy
  • well-/dedifferentiated

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacotherapy for liposarcoma : current state of the art and emerging systemic treatments. / Suarez-Kelly, Lorena P.; Baldi, Giacomo G.; Gronchi, Alessandro.

In: Expert Opinion on Pharmacotherapy, Vol. 20, No. 12, 01.01.2019, p. 1503-1515.

Research output: Contribution to journalReview article

@article{be63b1662b34420e8847d562f71a502d,
title = "Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments",
abstract = "Introduction: Liposarcomas are a heterogeneous group of soft tissue tumors that arise from adipose tissue and are one of the most common soft tissue sarcomas found in adults. Liposarcomas are subclassified into four subtypes with distinct histologic and biologic features that influence their treatment and management. Areas covered: This manuscript reviews the key clinicopathologic and cytogenic characteristics of the liposarcoma histologic subtypes and summarizes the results of recent clinical trials, treatment options, and future directions in the pharmacotherapy for the management of liposarcoma. Expert opinion: Despite significant advancements in the management of this disease, the treatment of liposarcoma continues to be a challenge. Surgical resection remains the mainstay of treatment for localized disease; however, use of systemic therapies in conjunction with surgery may be considered in patients where tumor shrinkage could reduce surgical morbidity and in patients with high-risk of micrometastatic disease. Anthracycline-based chemotherapy regimens remain the standard first-line treatment for unresectable/metastatic liposarcoma. Trabectedin and eribulin are currently the two most promising and evidenced-based second-line treatment options for liposarcomas. However, multiple clinical trials dedicated to patients with liposarcoma evaluating novel targeted agents are ongoing. Every effort should be made to enroll patients with liposarcoma into histotype-specific clinical trials.",
keywords = "Cytotoxic Chemotherapy, liposarcoma, myxoid/round cell, pleomorphic, targeted therapy, well-/dedifferentiated",
author = "Suarez-Kelly, {Lorena P.} and Baldi, {Giacomo G.} and Alessandro Gronchi",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/14656566.2019.1618271",
language = "English",
volume = "20",
pages = "1503--1515",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Pharmacotherapy for liposarcoma

T2 - current state of the art and emerging systemic treatments

AU - Suarez-Kelly, Lorena P.

AU - Baldi, Giacomo G.

AU - Gronchi, Alessandro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Liposarcomas are a heterogeneous group of soft tissue tumors that arise from adipose tissue and are one of the most common soft tissue sarcomas found in adults. Liposarcomas are subclassified into four subtypes with distinct histologic and biologic features that influence their treatment and management. Areas covered: This manuscript reviews the key clinicopathologic and cytogenic characteristics of the liposarcoma histologic subtypes and summarizes the results of recent clinical trials, treatment options, and future directions in the pharmacotherapy for the management of liposarcoma. Expert opinion: Despite significant advancements in the management of this disease, the treatment of liposarcoma continues to be a challenge. Surgical resection remains the mainstay of treatment for localized disease; however, use of systemic therapies in conjunction with surgery may be considered in patients where tumor shrinkage could reduce surgical morbidity and in patients with high-risk of micrometastatic disease. Anthracycline-based chemotherapy regimens remain the standard first-line treatment for unresectable/metastatic liposarcoma. Trabectedin and eribulin are currently the two most promising and evidenced-based second-line treatment options for liposarcomas. However, multiple clinical trials dedicated to patients with liposarcoma evaluating novel targeted agents are ongoing. Every effort should be made to enroll patients with liposarcoma into histotype-specific clinical trials.

AB - Introduction: Liposarcomas are a heterogeneous group of soft tissue tumors that arise from adipose tissue and are one of the most common soft tissue sarcomas found in adults. Liposarcomas are subclassified into four subtypes with distinct histologic and biologic features that influence their treatment and management. Areas covered: This manuscript reviews the key clinicopathologic and cytogenic characteristics of the liposarcoma histologic subtypes and summarizes the results of recent clinical trials, treatment options, and future directions in the pharmacotherapy for the management of liposarcoma. Expert opinion: Despite significant advancements in the management of this disease, the treatment of liposarcoma continues to be a challenge. Surgical resection remains the mainstay of treatment for localized disease; however, use of systemic therapies in conjunction with surgery may be considered in patients where tumor shrinkage could reduce surgical morbidity and in patients with high-risk of micrometastatic disease. Anthracycline-based chemotherapy regimens remain the standard first-line treatment for unresectable/metastatic liposarcoma. Trabectedin and eribulin are currently the two most promising and evidenced-based second-line treatment options for liposarcomas. However, multiple clinical trials dedicated to patients with liposarcoma evaluating novel targeted agents are ongoing. Every effort should be made to enroll patients with liposarcoma into histotype-specific clinical trials.

KW - Cytotoxic Chemotherapy

KW - liposarcoma

KW - myxoid/round cell

KW - pleomorphic

KW - targeted therapy

KW - well-/dedifferentiated

UR - http://www.scopus.com/inward/record.url?scp=85071651328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071651328&partnerID=8YFLogxK

U2 - 10.1080/14656566.2019.1618271

DO - 10.1080/14656566.2019.1618271

M3 - Review article

C2 - 31136210

AN - SCOPUS:85071651328

VL - 20

SP - 1503

EP - 1515

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -